• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by 111 Inc.

    4/30/24 6:11:25 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $YI alert in real time by email
    NT 20-F 1 dp210065_nt20f.htm FORM NT 20-F

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Checkone): ☐ Form 10-K  ☒ Form 20-F  ☐ Form 11-K ☐ Form 10-Q  ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR
       
     

    For Period Ended: December 31, 2023

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

    For the Transition Period Ended: __________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type. 

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. 

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    111, Inc.

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    3-4/F, No.295 ZuChongZhiRoad, Pudong New Area

    Address of Principal Executive Office (Street and Number)

     

    Shanghai, 201203, People’s Republic of China

    City, State and Zip Code

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒

    (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

     

    (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

     

    (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. 

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

     

     

     

    111, Inc. (the “Company”) has encountered a delay in assembling the information and finalizing the registrant's Annual Report for the fiscal year ended December 31, 2023 without incurring undue hardship and expense. In accordance with Rule 12b-25(b)(2)(ii) under the Securities Exchange Act of 1934, as amended, the Company endeavors to file its Annual Report on Form 20-F as soon as practical.

     

    PART IV — OTHER INFORMATION

     

    (1)Name and telephone number of person to contact in regard to this notification

     

    Junling Liu   +86   021-20536666
    (Name)   (Area Code)   (Telephone Number)

     

    (2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

     

    (3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☒ No ☐

     

    The Company currently does not expect to be able to file its Annual Report on Form 20-F for the year ended December 31, 2023 on a timely basis without unreasonable effort or expense because the Company is unable to finish preparing its financial statements, mainly the required supporting disclosures, for the periods to be included in the annual report by the prescribed filing deadline of April 30, 2024. The Company anticipates that it will file the Form 20-F no later than the fifteenth calendar day following the prescribed filing date.

     

    Forward-Looking Statements

     

    This notification includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The word “expects,” “anticipates” and similar terms and phrases are used in this notification to identify forward-looking statements. Risks, uncertainties and assumptions that could affect the Company’s forward-looking statements include, among other things, any changes to our anticipated financial results as a result of our independent registered public accounting firm completing its audit of the Company’s financial statements, the ability of us and our auditors to confirm information or data identified in the review, our ability to complete and file future periodic filings with the SEC on a timely basis and other risks and uncertainties discussed more fully in the Company’s filings with the SEC. Unless required by law, the Company expressly disclaims any obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

     

    111, Inc.
    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 30, 2024 By: /s/ Junling Liu
      Name: Junling Liu
      Title: Chief Executive Officer

     

     

     

     

     

     

     

     

     

     

    Get the next $YI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on 111, Inc. with a new price target

    Citigroup resumed coverage of 111, Inc. with a rating of Buy and set a new price target of $16.00

    4/15/21 6:56:01 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    111, Inc. Announces Third Quarter 2025 Unaudited Financial Results

    Transition from An Asset-Heavy Business Model to An Asset-Light Business ModelAchieved Quarterly Non-GAAP Net ProfitabilityMaintained Non-GAAP Operational Profitability for Three Consecutive QuartersAchieved Quarterly Positive Operating Cash FlowSHANGHAI, Dec. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total operating expenses were RMB180.3 million (US$25.3 million)

    12/17/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoYMaintained Positive Operating Cash Flow in the First Half of the YearSHANGHAI, Sept. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total operating expenses were RMB185.3 million (US$25.9 million), an improvement of 9.3% compared to RMB204.3 million in

    9/17/25 2:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces First Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained Quarterly Positive Operating Cash FlowSHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year.Total operating expenses

    6/19/25 3:03:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    SEC Filings

    View All

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    12/17/25 6:13:16 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    9/17/25 6:09:10 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form 20-F/A filed by 111 Inc.

    20-F/A - 111, Inc. (0001738906) (Filer)

    8/29/25 6:03:53 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Financials

    Live finance-specific insights

    View All

    111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

    Achieved First-Ever Annual Operating ProfitBottom Line Improved by RMB332.7 Million YoY in 2024Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoYAchieved First-Ever Annual Positive Operating Cash FlowSHANGHAI, March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Four

    3/20/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow

    SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Q

    2/20/25 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

    Maintained Operational Profitability for the Third Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoYHeld Positive Operating Cash Flow for Three Consecutive QuartersSHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same

    11/27/24 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Leadership Updates

    Live Leadership Updates

    View All

    111, Inc. Announces Change to Board of Directors

    SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr

    11/4/24 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 Announces Appointment of New Auditor

    SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced  the appointment of  Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar

    7/19/24 8:45:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")

    9/23/22 12:30:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    2/27/24 8:02:40 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    7/17/23 9:00:05 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    10/31/22 7:57:04 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples